Everolimus Tablet, For Suspension
Product Images NDC 70377-090

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 41 technical images submitted to the FDA as part of the official labeling for Everolimus (NDC 70377-090). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biocon Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

2-mg-desiflex-label-carton.jpg (2 mg Carton Desiflex Label)

2-mg-desiflex-label-carton.jpg (2 mg Carton Desiflex Label)
This is a description for Everolimus Tablets for Oral Suspension. Each tablet contains 2 mg of everolimus USP. The tablets must be dispersed in water and not swallowed whole, chewed, or crushed. The carton contains 4 blister cards of 7 tablets each, totaling 28 tablets for oral suspension. Dosage instructions can be found in the package insert. The medication should be stored at 20°C to 25°C and protected from light and moisture. Manufactured by Biocon Pharma Inc. in the USA and Biocon Pharma Limited in India. For more information, contact 1-866-924-6266.*
FDA Label Image

2-mg-pealable-foil.jpg (2 mg Pealable Foil)

2-mg-pealable-foil.jpg (2 mg Pealable Foil)
This is a description of a medication called Everolimus in tablet form for oral suspension, with a dosing of 2 mg. The text also mentions an empty cavity and various symbols and characters that are not fully clear.*
FDA Label Image

3-mg-desiflex-label-carton.jpg (3 mg Carton Desiflex Label)

3-mg-desiflex-label-carton.jpg (3 mg Carton Desiflex Label)
This text contains information about Everolimus Tablets for Oral Suspension. Each tablet contains 3 mg of everolimus USP. The tablets must be dispersed in water and not swallowed whole, chewed, or crushed. The product comes in a carton containing 4 blister cards of 7 tablets each. The manufacturer is Biocon Pharma Inc. The dosage instructions can be found in the package insert. The tablets should be stored at 20°C to 25°C; excursions permitted between 15°C to 30°C. For more information, you can contact 1-866-924-6266.*
FDA Label Image

3-mg-pealable-foil.jpg (3 mg Pealable Foil)

3-mg-pealable-foil.jpg (3 mg Pealable Foil)
This text appears to be a description of Everolimus tablets or oral suspension with a strength of 3 mg. It mentions a prescription drug, possibly for medical use. The text also indicates an empty cavity for the oral suspension. The text is not clearly readable and may not provide detailed information.*
FDA Label Image

5-mg-desiflex-label-carton.jpg (5 mg Carton Desiflex Label)

5-mg-desiflex-label-carton.jpg (5 mg Carton Desiflex Label)
This text contains information about Everolimus Tablets for Oral Suspension. Each tablet contains 5 mg of everolimus USP and must be dispersed in water before use. The tablets should not be swallowed whole, chewed or crushed. The product comes in a carton with 4 individual blister cards of 7 tablets each. The dosage information can be found in the package insert. The storage temperature should be between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). The manufacturer is Biocon Pharma Inc. in the USA and Biocon Pharma Limited in Bengaluru, India. For more information, you can call 1-866-924-6266.*
FDA Label Image

5-mg-pealable-foil.jpg (5 mg Pealable Foil)

5-mg-pealable-foil.jpg (5 mg Pealable Foil)
FDA Label Image

Cont-label-2mg (Cont Label 2mg)

Cont-label-2mg (Cont Label 2mg)
This is a product label for Everolimus Tablets for Oral Suspension. The tablets contain 2 mg of everolimus USP and must be dispersed in water, not swallowed whole, chewed, or crushed. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F). It provides a contact number for more information and states to keep the product out of reach of children. The product is manufactured by Biocon Pharma Limited in Bengaluru, India, and manufactured for Biocon Pharma Inc. in Iselin, NJ, USA. It also includes information on batch serialization coding and expiration date.*
FDA Label Image

Cont-label-3mg (Cont Label 3mg)

Cont-label-3mg (Cont Label 3mg)
This text is a description of Everolimus Tablets for Oral Suspension. Each tablet contains 3 mg of everolimus USP. The tablets must be dispersed in water; not swallowed whole, chewed, or crushed. The dosage information can be found in the package insert. The product should be stored at 68°F to 77°F and protected from light and moisture. It is recommended to keep the medication out of reach of children. For more details, contact 1-866-924-6266. The tablets are manufactured by Biocon Pharma Inc. in Iselin, NJ, USA, and by Biocon Pharma Limited in Bengaluru, India.*
FDA Label Image

Cont-label-5mg (Cont Label 5mg)

Cont-label-5mg (Cont Label 5mg)
This text contains essential information about Everolimus Tablets for Oral Suspension. The tablets are to be dispersed in water and not swallowed whole, chewed, or crushed. Each tablet contains 5mg of everolimus USP for oral use. The package insert provides dosage instructions. The tablets must be stored at 20°C to 25°C and protected from light and moisture. The manufacturer is Biocon Pharma Inc. in Iselin, NJ, USA, and Biocon Pharma Limited in Bengaluru, India. The text also includes a contact number for more information and guidelines on keeping the drug out of children's reach. Batch serialization coding is mentioned for product tracking.*
FDA Label Image

Image-01 (Image 01)

Image-01 (Image 01)
FDA Label Image

Image-02 (Image 02)

Image-02 (Image 02)
FDA Label Image

Image-04 (Image 04)

Image-04 (Image 04)
FDA Label Image

Image-05 (Image 05)

Image-05 (Image 05)
This is a list of items related to measuring devices, including a plunger, barrel, and volume indicators. These tools are commonly used for measuring and quantifying volumes accurately in various settings.*
FDA Label Image

Image-06 (Image 06)

Image-06 (Image 06)
FDA Label Image

Image-07 (Image 07)

Image-07 (Image 07)
FDA Label Image

Image-08 (Image 08)

Image-08 (Image 08)
FDA Label Image

Image-10 (Image 10)

Image-10 (Image 10)
FDA Label Image

Image-11 (Image 11)

Image-11 (Image 11)
FDA Label Image

Image-12 (Image 12)

Image-12 (Image 12)
FDA Label Image

Image-13 (Image 13)

Image-13 (Image 13)
FDA Label Image

Image-14 (Image 14)

Image-14 (Image 14)
FDA Label Image

Image-15 (Image 15)

Image-15 (Image 15)
FDA Label Image

Image-16 (Image 16)

Image-16 (Image 16)
FDA Label Image

Image-17 (Image 17)

Image-17 (Image 17)
FDA Label Image

Image-18 (Image 18)

Image-18 (Image 18)
FDA Label Image

Image-19 (Image 19)

Image-19 (Image 19)
FDA Label Image

Image-20 (Image 20)

Image-20 (Image 20)
FDA Label Image

Image-21 (Image 21)

Image-21 (Image 21)
FDA Label Image

Image-22 (Image 22)

Image-22 (Image 22)
FDA Label Image

Image-23 (Image 23)

Image-23 (Image 23)
FDA Label Image

Image-24 (Image 24)

Image-24 (Image 24)
FDA Label Image

Image-25 (Image 25)

Image-25 (Image 25)
FDA Label Image

Image-26 (Image 26)

Image-26 (Image 26)
FDA Label Image

Image-27 (Image 27)

Image-27 (Image 27)
FDA Label Image

Image-29 (Image 29)

Image-29 (Image 29)
FDA Label Image

Image-30 (Image 30)

Image-30 (Image 30)
FDA Label Image

Image-31 (Image 31)

Image-31 (Image 31)
FDA Label Image

Image-32 (Image 32)

Image-32 (Image 32)
FDA Label Image

Image-33 (Image 33)

Image-33 (Image 33)
FDA Label Image

Image-34 (Image 34)

Image-34 (Image 34)
FDA Label Image

Image-35 (Image 35)

Image-35 (Image 35)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.